ABSTRACT
In 2020, the death of physicians due to COVID-19 in Indonesia raises questions about the condition that caused the incident. What was the situation at the early stage of the pandemic, the use of WHO’s Risk Assessment questionnaire, and what lesson was learned about it? A Cross-sectional survey, using blast mail surveys targeting the Government-owned Public Health Center Physician’s WhatsApp application across Indonesia had held. A Self-administered questionnaire, using WHO’s “Risk assessment and management of exposure of health care workers in the context of Covid-19” which has been translated into Bahasa Indonesia. As result, there were 2.099 responses eligible for this study. At the early stage of the pandemic, 99,29% of Government-owned Public Health Center Physicians were at high risk of COVID-19 exposure. Its because on average 64,23% of the respondent not use PPE correctly, 15,53% of respondents still performing actions that produced aerosols in health centers, or 22,73% of respondents got biological accidents. At the early stage of the pandemic in Indonesia marked by the scarcity of PPE, the lack of awareness from the physicians and or the government make a double burden on the physicians. As for the use of questionnaires, there were challenging issues in conducting the study, such as respondents feeling redundant in answering the questionnaire. It is recommended that the Central and Regional Governments, health centers, and hospitals increase their commitment to protecting physicians from possible exposure to Covid-19, among others, through meeting standard APD needs, maintaining the cleanliness of health care facilities, updating the skill and knowledge about pandemics on physicians, and providing adequate incentives. The physician is also expected to adapt in many ways.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Institute of Health Research and Development, Ministry of Health, Indonesia
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health Research Ethics Committee, National Institute of Health Research and Development, Ministry of Health, Indonesia (LB. 02.01/2/KE.665/2020)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are protected by the Ministry of Health of Indonesia and are unsuitable for public sharing
